SEC Form SC 13G filed by Harvard Bioscience Inc.
$HBIO
Biotechnology: Laboratory Analytical Instruments
Industrials
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/9/2025 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 3/10/2023 | $3.00 → $4.00 | Speculative Buy → Buy | The Benchmark Company |
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience"), a leading provider of innovative laboratory equipment, is pleased to announce the expansion of its distribution agreement with Fisher Scientific, a part of Thermo Fisher Scientific, one of the world's largest and most trusted scientific suppliers. Under this new agreement, Fisher Scientific will now offer Harvard Bioscience pumps, spectrophotometers, and BTX electroporation systems in the United States, complementing the existing distribution agreement in Europe. This agreement provides Harvard Bioscience access to hundreds of Fisher Scientific sales represen
HOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience") today announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. Mr. DeNelsky will also serve on the Board's Nominating and Governance Committee. "We are pleased to announce Steve as the newest member of our Board of Directors at such an important time for Harvard Bioscience," said John Duke, President & CEO. "His knowledge across the verticals we operate in, as well as his expertise in guiding life sciences companies on financial strategy will be invaluable as we move forward." "I'm honored to join the Board and lo
Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by OperationsThird Quarter 2025 Guidance Reflects Improved Operations and Strong Financial DisciplineNew Credit Amendment Signed, Extending Refinance Deadline to December 5th HOLLISTON, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2025. "We made solid progress in the second quarter exceeding our revenue guidance. In my short time as CEO, I have already seen first-hand the dedication of our team. The fundamentals of the business remain intact with attractive margins a
KeyBanc Capital Markets downgraded Harvard Biosci from Overweight to Sector Weight
The Benchmark Company upgraded Harvard Biosci from Speculative Buy to Buy and set a new price target of $4.00 from $3.00 previously
KeyCorp reiterated coverage of Harvard Bioscience with a rating of and set a new price target of $9.00 from $6.00 previously
8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
10-Q - HARVARD BIOSCIENCE INC (0001123494) (Filer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
HOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience") today announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. Mr. DeNelsky will also serve on the Board's Nominating and Governance Committee. "We are pleased to announce Steve as the newest member of our Board of Directors at such an important time for Harvard Bioscience," said John Duke, President & CEO. "His knowledge across the verticals we operate in, as well as his expertise in guiding life sciences companies on financial strategy will be invaluable as we move forward." "I'm honored to join the Board and lo
Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board membersQ2 '25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin guidance HOLLISTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company" or "Harvard Bioscience") today announced a CEO succession plan under which John Duke will assume the role of President & CEO following the planned retirement of Jim Green, effective July 28, 2025. Jim Green will be retiring from his President, CEO & Chairman roles at Harvard Bioscience after more than 8 years as Chairman and 6 years as Pre
HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company's board of directors. "We are pleased to welcome John to Harvard Bioscience's board," said Katherine Eade, Lead Independent Director. "John brings deep experience in life science tools and business execution and has a track record of driving growth and operational excellence." Jim Green, President and CEO, sa
Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by OperationsThird Quarter 2025 Guidance Reflects Improved Operations and Strong Financial DisciplineNew Credit Amendment Signed, Extending Refinance Deadline to December 5th HOLLISTON, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2025. "We made solid progress in the second quarter exceeding our revenue guidance. In my short time as CEO, I have already seen first-hand the dedication of our team. The fundamentals of the business remain intact with attractive margins a
HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 11, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, w
HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the first quarter ended March 31, 2025. Jim Green, Chairman and CEO, said, "First quarter revenues were in line with our expectations, reflecting typical Q4 to Q1 seasonality as well as uncertainty surrounding NIH funding and the evolving tariff situation, especially in relation to sales to China." We are excited by the emerging adoption of our breakthrough MeshMEA™ organoid systems by academic and biopharma customers and encouraged by the market reception of our new SoHo™ telemetry systems. In addition, we remain focused on managing costs and ex
SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)